Table 1 Functions of m6A related enzymes and targets in CRC
Molecules | Type | Related Microenvironment | Targets | Effects | References |
|---|---|---|---|---|---|
METTL3 | Writer | Metabolic | CCNE1 | Interregulate with intestinal metabolites and promote CRC proliferation | Zhu et al. (2020) |
METTL3 | Writer | Metabolic | PTTG3P | Induce glycolysis and CRC proliferation | Zheng et al. (2021) |
METTL3 | Writer | Metabolic | LDHA | Regulate glucose metabolism in CRC, and mediate the resistance of CRC cells to 5-FU | Zhang et al. (2022a) |
METTL14 | Writer | Metabolic | miR-149-3p | Promote intestinal inflammation and CRC | Cao et al. (2021b) |
KIAA1429 | Writer | Metabolic | HK2 | Accelerate aerobic glycolysis and the production of malignant phenotypes in CRC | Li et al. (2022a) |
YTHDF1 | Reader | Metabolic | GLS | Promote CRC resistance to cisplatin | Chen et al. (2021b) |
YTHDF2 | Reader | Metabolic | DEGS2 | Inhibit dysregulation of lipid metabolism and proliferation and migration of CRC | Guo et al. (2021) |
IMP2 | Reader | Metabolic | ZFAS1 | Mediate the energy metabolism of cell mitochondria, promote the proliferation of CRC and inhibit the apoptosis of CRC cells | Lu et al. (2021) |
METTL3 | Writer | Hypoxic | HIF-1a | Promote the progression of CRC under hypoxia | Yang et al. (2021) |
YTHDF1 | Reader | Hypoxic | HIF-1a | Promote the formation of the hypoxic microenvironment and the progression of CRC | Yang et al. (2021) |
FTO | Eraser | Hypoxic | MTA1 | Inhibit CRC cell growth and metastasis in vivo | Ruan et al. (2021) |
METTL3 | Writer | Inflammatory | SOCS2 | Induce CRC cell proliferation and maintain tumorigenicity of CRC | Xu et al. (2020b) |
METTL3 | Writer | Inflammatory | STAT1 | Promote M1-type macrophage polarization and inhibit M2-type macrophage formation | Liu et al. (2019) |
IGF2BP2/3 | Reader | Inflammatory | EphA2, VEGFA | Promote angiogenesis in CRC | Liu et al. (2022a) |
METTL3 | Writer | Immune | Sec62 | Maintain the stem cell-like phenotype and resistance to chemotherapeutic agents in CRC | Liu et al. (2021) |
METTL3 | Writer | Immune | TCF7L2 | Regulate CRC resistance to cetuximab | Liu et al. (2022c) |
METTL3 | Writer | Immune | NCALD | Inhibit CRC sensitivity to 5-FU | Pan et al. (2022) |
METTL3 | Writer | Immune | BHLHE41 | Enhance the migration of MDSCs in vitro and inhibit the activation and proliferation of CD4+ T and CD8+ T cells | Chen et al. (2022) |
METTL14 | Writer | Immune | – | Regulate infiltration of CD8+T cells | Dong et al. (2021) |
METTL14 | Writer | Immune | lncRNA XIST | The deletion of this gene can promote the proliferation and invasion of CRC | Yang et al. (2020) |
METTL3/METTL14 | Writer | Immune | STAT1 | The deletion of these genes can promote IFN-γ secretion and increase CD8+T cell infiltration, thus improving the sensitivity of CRC against PD-1 treatment | Wang et al. (2020b) |
YTHDF1 | Reader | Immune | – | The deletion of this gene can improve the antigen presentation ability of DCs and activation of CD8+ T cells in vivo | Shulman and Stern-Ginossar (2020) |
YTHDF3 | Reader | Immune | eLF2AK2 | Promote translation of drug-resistant genes | Zhao et al. (2022) |
ALKBH5 | Eraser | Immune | Mct4/Slc16a3 | Regulate infiltration of Tregs and MDSCs, plays a critical role in the efficacy of anti-PD-1 therapy | Li et al. (2020b) |
FTO | Eraser | Immune | – | Gene deletion inhibits PD-L1 expression in CRC cells | Tsuruta et al. (2020) |